国药一致(000028)：业绩预告略超预期 业务结构调整取得良好成效

Group 1 - The core viewpoint of the article indicates that the company expects a significant increase in net profit for 2025, with a forecasted range of 1.055 billion to 1.215 billion yuan, representing a year-on-year growth of 64.20% to 89.11% [1] - The company plans to optimize its distribution and retail business structures, with a focus on cost reduction and efficiency improvements, particularly through strategic adjustments in store layouts and product structures [2] - The company anticipates a substantial reduction in goodwill and intangible asset impairment provisions for 2025, estimating a decrease of 639.93 million to 729.93 million yuan compared to the previous year [2] Group 2 - The company is actively expanding into new business areas, including the establishment of a medical device center and a medical management center to enhance its capabilities in hospital access for innovative drug products [3] - Profit forecasts have been revised upward, with net profit predictions for 2025 and 2026 increased by 22.1% and 21.5% respectively, and a new forecast for 2027 introduced, indicating a growth rate of 71.1% [4] - The current stock price corresponds to a price-to-earnings ratio of 11.7 times for 2026 and 10.6 times for 2027, with a target price of 32.13 yuan, suggesting a potential upside of 25.7% from the current price [4]